Bioretec's High-Stakes Gamble: Can Innovation Outpace Deep Financial Loss?

TAMPERE, FINLAND – February 13, 2026 – Finnish medical device pioneer Bioretec has reported a tumultuous 2025, a year defined by the stark contrast of significant financial decline and major regulatory victories. The company's full-year financial statements, released today, paint a picture of a firm in deep transition, with net sales plummeting and losses doubling, even as its innovative biodegradable implants gain critical approvals in key global markets.

In what new CEO Sarah van Hellenberg Hubar-Fisher described as a "year of rebuilding and renewed focus," Bioretec has undergone a radical strategic and operational overhaul. The company is betting that this painful, foundational reset, combined with the unique clinical promise of its technology, will pave the way for long-term growth, asking investors to look beyond the challenging bottom line.

A Balance Sheet Under Strain

The financial results for 2025 are stark. Bioretec's net sales fell 22.5% to EUR 3.52 million, down from EUR 4.54 million in 2024. The decline was even more pronounced in the second half of the year, dropping nearly 42% compared to the same period in the prior year. This sales slump had a severe impact on profitability, with the EBITDA loss widening to EUR -8.48 million from EUR -4.05 million in 2024. The net loss for the period nearly doubled, reaching EUR -9.48 million.

A key driver behind the mounting losses is a massive increase in research and development spending. R&D expenditure surged to 85.8% of net sales, a dramatic jump from 48.0% in 2024. While this highlights the company's commitment to its product pipeline, it also underscores the heavy investment required to bring its next-generation RemeOs™ products to market.

The company's performance was significantly impacted by a strategic shift in its largest market, the United States. Bioretec began transitioning from a stocking distributor model to a direct distribution approach. While the company states this move is designed to provide "stronger transparency, predictability and long-term quality of net sales," it caused major short-term disruption. U.S. sales fell by 56% in 2025 as the company absorbed changes in ordering cycles and built new commercial infrastructure from the ground up.

"Our financial results reflect a year of taking one step back to reposition for lasting progress," CEO Sarah van Hellenberg Hubar-Fisher stated in the company announcement. "Absorbing significant changes in leadership roles, commercial capabilities, distribution models, and ordering cycles were investments in resilience and scalability."

A Sweeping Strategic and Leadership Reset

The financial turmoil coincided with a year of sweeping internal change. The company saw a complete overhaul of its leadership, beginning with the resignation of CEO Alan Donze in May. Sarah van Hellenberg Hubar-Fisher, initially appointed as interim CEO, took the permanent role in August and spearheaded a comprehensive review of the company's strategy.

This review led to a dramatic course correction. In October, Bioretec withdrew its highly ambitious financial targets—which had projected reaching EUR 65 million in sales by 2028—deeming them "unattainable." In December, it issued a new, far more conservative strategy for 2026-2028, now targeting net sales exceeding EUR 10 million by the end of 2028.

The restructuring also involved "change negotiations" within its Finnish production and marketing functions to improve efficiency. This was part of a broader effort to create what the company calls a "more agile commercial organization" capable of executing the new, more focused strategy. The reset was funded in part by a successful EUR 9.2 million rights issue completed in June, shoring up a balance sheet under pressure from operating cash outflows that reached EUR -9.76 million for the year.

Breakthroughs in Biodegradable Technology

While the financial and organizational story is one of struggle and restructuring, the narrative around Bioretec's technology is one of significant progress. The company's RemeOs™ product line, which features implants made from a high-performance magnesium alloy that is absorbed and replaced by bone, achieved several critical milestones in 2025.

In January, the RemeOs™ Trauma Screw received its CE mark, opening the door for commercialization across Europe. More importantly for its long-term prospects in the lucrative U.S. market, the product was granted Transitional Pass-Through Payment (TPT) status by the Centers for Medicare & Medicaid Services (CMS) in October. This designation helps hospitals receive separate, additional payment for the device, mitigating financial barriers to adoption.

Capping off the year, the RemeOs™ DrillPin was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) in December. This marks Bioretec's third such designation, a rare achievement that signals the FDA's belief that the technology provides a more effective treatment for life-threatening or irreversibly debilitating conditions. These designations can expedite the development and review process for new medical devices.

These regulatory and reimbursement wins are crucial, as they validate the clinical and economic potential of Bioretec's core value proposition: eliminating the need for a second surgery to remove traditional metal implants. This promise is central to the company’s effort to capture a piece of the global bioabsorbable implants market, which is projected to grow at a compound annual rate of over 6% and reach more than US$ 11 billion by 2033.

"These achievements affirm the clinical and economic relevance and differentiation of Bioretec's portfolio and highlight our capacity to lead this emerging segment," Hubar-Fisher noted.

With a new leadership team, a rebuilt commercial strategy, and a more realistic set of targets, Bioretec enters 2026 with a clearer path but immense pressure to perform. The "rebuilding phase was essential," according to the CEO, but now the company must prove that its groundbreaking technology can translate into the commercial momentum and financial results needed to justify the painful year of transition. The focus now shifts from restructuring to execution.